When an oral sermorelin product is described as highly absorbed, the useful question is: what was measured, in whom, and with which formulation? A tablet's listed ingredient amount is not a measurement of how much active medicine reaches its site of action. Dissolving quickly also does not establish a clinical benefit.
FDA describes bioavailability in terms of the rate and extent of drug absorption and availability at the site of action. That is a property to investigate with appropriate evidence, not something established by words such as “sublingual,” “advanced,” or “fast dissolving” alone.
A tablet dissolving in the mouth does not establish how much sermorelin reaches the bloodstream. Ask for evidence on the exact preparation.
Separate four different claims
Swipe sideways to read the full table. You can also select the table and use the arrow keys.
| Claim | Evidence that would help answer it |
|---|---|
| The tablet dissolves | Tests of the actual preparation's dissolution |
| The ingredient is absorbed | Suitable exposure measurements for that formulation and route |
| It affects the GH pathway | Relevant hormone measurements interpreted in context |
| It improves a health outcome | Clinical outcome data with an appropriate comparison |
These questions are related but distinct. A study addressing one step should not be presented as proof of every later step. Our tablets-and-troches guide discusses the practical differences between products marketed under broad oral terminology.
Sublingual is not the same instruction as swallowed
A product intended to dissolve under the tongue has different administration instructions from a swallowed capsule. A dissolving tablet can also contain multiple ingredients. Ask the pharmacy which route is intended and follow the instructions for that exact preparation.
Do not change how long a product is held in the mouth or take extra tablets to compensate for an assumed absorption percentage. Without validated formulation-specific information and a prescriber's plan, that calculation does not establish an appropriate treatment amount.
Intranasal data cannot supply an oral percentage
A 1993 human GHRH(1-29) study compared intravenous and intranasal administration and reported low nasal bioavailability for the studied preparation. It did not test a modern sublingual tablet. Its nasal percentage should not be relabeled as the absorption of all non-injected sermorelin.
The nasal-spray guide explains the original route-specific research. It is useful precisely because it shows that route and preparation matter. Using a percentage from the wrong route creates a false appearance of precision rather than a reliable comparison.
What our source review could establish
The searches used for this article did not identify a controlled human study establishing a general absorption percentage or injection equivalence for the current compounded oral products discussed in this publication. Search results included provider explanations and studies of different interventions, which do not fill that gap.
This does not prove that every oral preparation has zero absorption. It means we cannot support a universal percentage or equivalence claim from the sources reviewed. Ask a provider offering such a figure for the full study and confirmation that it tested the actual preparation being dispensed.
Compare convenience without assuming equal results
Avoiding needles may be an important practical preference. It is reasonable to discuss that preference while also asking what is known about the chosen route's clinical performance. Convenience and strength of evidence can be considered separately without pretending one proves the other.
The route comparison helps organize those questions. FDA notes that compounded drugs are not FDA-approved, so a prescription or a pharmacy label alone is not evidence that a tablet has undergone the same approval review as a finished approved product. A useful explanation should clearly identify both the practical appeal and the limits of the supporting data.
Sources & further reading
Provider pages describe offers; they do not independently establish treatment benefits. Sources checked September 20, 2026.
This article is education, not a diagnosis, prescription, or dosing plan. Discuss treatment and alternatives with a licensed clinician who knows your history. Compounded medications are not FDA-approved.